Amarin Corporation Investor Relations Material
Latest events
Investor Update
Amarin Corporation
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Amarin Corporation plc
Access all reports
Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular health. The company's primary product is an omega-3-based prescription therapy designed to reduce cardiovascular risk in patients with elevated triglyceride levels. Amarin's research and development efforts center on addressing unmet needs in cardiovascular care through innovative lipid management treatments. The company operates globally, with a focus on expanding its product offerings and advancing cardiovascular treatment options. The company is headquartered in Dublin, Ireland, and its shares are listed on the Nasdaq.
Key slides for Amarin Corporation plc
Q1 2025
Amarin Corporation plc
Q1 2025
Amarin Corporation plc
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
AMRN
Country
🇺🇸 United States